Skip to content

Opko Health OPK Gross Profit

Gross Profit at other companies

HRO
HarrowHROW
$27.05M-16.3%
Abbott logo
AbbottABT
$6.27B+6.5%
Amneal Pharmaceuticals, Inc. logo
Amneal Pharmaceuticals, Inc.AMRX
$320.11M+25.1%
ALN
Alnylam PharmaceuticalsALNY
$959.66M+83.1%
Quest Diagnostics logo
Quest DiagnosticsDGX
Exelixis logo
ExelixisEXEL

Segments

By segment

See full
Pharmaceutical$29.71M+22.3%
Diagnostics$16.04M-12.5%

Other financials

Income statement

See full
Revenue$124.2M-17.2%
Operating income-$51.0M+24.0%
Net income-$54.8M+18.9%
EPS (diluted)-$0.07+30.0%

Balance sheet

See full
Cash & equivalents$40.6M-62.5%
Total debt$52.8M-4.2%
Total equity$1.2B-8.2%
Total assets$1.9B-12.8%

Cash flow

See full
Operating cash flow-$19.3M+44.1%
CapEx$1.8M-42.6%
Free cash flow-$21.1M+44.0%

Valuation

See full
Market cap$1.13B+10.0%
P/S1.9×+0.5×

Profitability

See full
Gross margin36%+4.2pp
Operating margin-17.4%-5.6pp
Net margin-36.6%-44.8pp
FCF margin-30%+0.1pp

Returns & leverage

See full
Return on equity-16.9%-21.7pp
Debt / equity0.0×
Current ratio3.6×+1.1×

Where this comes from

Calculated from Opko Health’s reported figures.

The official record: Opko Health’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opko Health's gross profit.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opko Health's gross profit?
Opko Health (OPK) reported gross profit of $45.76M in Q1 2026.
How has Opko Health's gross profit changed year-over-year?
Opko Health's gross profit increased by 7.4% year-over-year, from $42.62M to $45.76M.
What is the long-term trend for Opko Health's gross profit?
Over 3 years (2022 to 2025), Opko Health's gross profit has grown at a -10.6% compound annual growth rate (CAGR), from $288.22M to $205.94M.
What does gross profit mean?
Revenue minus cost of revenue — the profit available to cover operating expenses, representing the company's pricing power and production efficiency.